ReviewJournal of Cancer2017
Central Role of CEMIP in Tumorigenesis and Its Potential as Therapeutic Target.
Review in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03679910 (Evaluation of Cell Migration Inducing Protein), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Cell Migration Inducing Protein (CEMIP) in Diagnosis of Pancreatic Carcinoma in Comparison With Other Traditional Markers
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery.Materials today. Bio · 2026Review
- CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC.BBA advances · 2026Article
- Evaluation of CEMIP in diagnosis of pancreatic carcinoma in comparison with other traditional markers.Scientific reports · 2025Article
- Upregulated CEMIP promotes intervertebral disc degeneration via AP-1-mediated change in chromatin accessibility.Clinical and translational medicine · 2025Article
- The CEMIP Hyaluronidase is Elevated in Oligodendrocyte Progenitor Cells and Inhibits Oligodendrocyte Maturation.ASN neuro · 2025Article
- Distinct chemical structures inhibit the CEMIP hyaluronidase and promote oligodendrocyte progenitor cell maturation.The Journal of biological chemistry · 2024Article
- CEMIP induces TGF-β/Smad signaling to promote keloid development by binding to SPARC.Clinics (Sao Paulo, Brazil) · 2024Article
- Prostate cancer genetic risk and associated aggressive disease in men of African ancestry.Nature communications · 2023Article
- Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway.Medical oncology (Northwood, London, England) · 2023Article
- 'Two-faces' of hyaluronan, a dynamic barometer of disease progression in tumor microenvironment.Discover oncology · 2023Review
- Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases.Cell death & disease · 2023Article
- CEMIP promotes extracellular matrix-detached prostate cancer cell survival by inhibiting ferroptosis.Cancer science · 2022Article
- Cell migration inducing hyaluronidase 1 promotes growth and metastasis of papillary thyroid carcinoma.Bioengineered · 2022Article
- ATF4/CEMIP/PKCα promotes anoikis resistance by enhancing protective autophagy in prostate cancer cells.Cell death & disease · 2022Article
- Article
- Secreted KIAA1199 promotes the progression of rheumatoid arthritis by mediating hyaluronic acid degradation in an ANXA1-dependent manner.Cell death & disease · 2021Article
- High Expression of CEMIP Correlates Poor Prognosis and the Tumur Microenvironment in Breast Cancer as a Promisingly Prognostic Biomarker.Frontiers in genetics · 2021Article
- Transcriptomic and Proteomic Profiling of Human Stable and Unstable Carotid Atherosclerotic Plaques.Frontiers in genetics · 2021Article
- Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT.Journal of Cancer · 2021Article
- Versican: A Dynamic Regulator of the Extracellular Matrix.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CEMIP (KIAA1199) was identified as migratory indicator protein which had been crudely studied in the last decade. Firstly its mutation site was reported to cause hearing loss due to the folding change of protein structure, meanwhile the over-expression of CEMIP referred to dreadful invasion and uncontrolled proliferation of tumor with distant metastasis, dedifferentiation, and limited survival opportunity of patients. Especially, over-expressed CEMIP also protected malignant tumor from strict microenvironment in hypoxia, low glucose and cracked barrier, leading to enhanced adaptability of tumor by stimulating the Wnt, EGFR, FGFR pathway. Here, we intend to elaborate the clinical function and dysregulation of CEMIP under the tumorous circumstance since CEMIP plays an important role in cytokine pathway and its over-expression in tumors provide a novel target for individual therapy. Targeting CEMIP would thereby dysregulate the cytokine pathway which would in turn, decide the growth and death of the vicious tumour cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.